Ebb & Flow

Amgen investors were initially relieved after Thursday's votes by FDA's Oncologic Drugs Advisory Committee not to remove chemotherapy-induced anemia from the labels of erythropoiesis-stimulating agents. The stock closed the day up $2.19 to $47.18.

But on further reflection on what the restrictions might mean for Aranesp oncology revenue, the shares gave back their gains on Friday, as the stock closed off $2.72 to $44.46. The shares were still up $0.28 on the week, adding $304.4 milion in market cap...